Tetraphase Pharms Drug Patent Portfolio

Tetraphase Pharms owns 1 orange book drug protected by 4 US patents Given below is the list of Tetraphase Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10961190 Crystalline forms of eravacycline 19 Oct, 2037
Active
US11578044 Crystalline forms of eravacycline 19 Oct, 2037
Active
US8906887 C7-fluoro substituted tetracycline compounds 28 Dec, 2030
Active
US8796245 C7-fluoro substituted tetracycline compounds 07 Aug, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Tetraphase Pharms.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8906887
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8906887
Recordation of Patent Grant Mailed 14 Feb, 2023 US11578044
Patent Issue Date Used in PTA Calculation 14 Feb, 2023 US11578044
Email Notification 26 Jan, 2023 US11578044
Issue Notification Mailed 25 Jan, 2023 US11578044
Dispatch to FDC 09 Jan, 2023 US11578044
Application Is Considered Ready for Issue 09 Jan, 2023 US11578044
Supplemental Papers - Oath or Declaration 05 Jan, 2023 US11578044
Issue Fee Payment Received 05 Jan, 2023 US11578044
Issue Fee Payment Verified 05 Jan, 2023 US11578044
Mail Notice of Allowance 06 Oct, 2022 US11578044
Email Notification 06 Oct, 2022 US11578044
Electronic Review 06 Oct, 2022 US11578044
Notice of Allowance Data Verification Completed 03 Oct, 2022 US11578044


Tetraphase Pharms Drug Patents' Oppositions Filed in EPO

Tetraphase Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 18, 2018, by Sandoz Ag. This opposition was filed on patent number EP15180611A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15180611A Jul, 2018 Sandoz AG Revoked


Tetraphase Pharms's Family Patents

Tetraphase Pharms drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 19.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Tetraphase Pharms Drug List

Given below is the complete list of Tetraphase Pharms's drugs and the patents protecting them.


1. Xerava

Xerava is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10961190 Crystalline forms of eravacycline 19 Oct, 2037
(13 years from now)
Active
US11578044 Crystalline forms of eravacycline 19 Oct, 2037
(13 years from now)
Active
US8906887 C7-fluoro substituted tetracycline compounds 28 Dec, 2030
(6 years from now)
Active
US8796245 C7-fluoro substituted tetracycline compounds 07 Aug, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xerava's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List